Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 18/500,032. The patent covers methods of using LP-284 to treat mantle cell lymphoma (MCL), double-hit lymphoma (DHL), and other blood cancers. The allowed claims include LP-284 as a monotherapy and in combination with several classes of anti-cancer agents. Once issued, the patent is expected to extend LP-284 intellectual property protection into 2042, adding method-of-use protection to Lantern's existing composition-of-matter patent estate.
This development is significant for Lantern Pharma and the broader oncology community. LP-284 is currently being evaluated in an ongoing Phase 1a dose-escalation clinical trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma and solid tumors. The compound, developed through the company's RADR® artificial intelligence platform, has received three FDA Orphan Drug Designations, including for MCL, high-grade B-cell lymphoma with MYC and BCL2 rearrangements, and soft tissue sarcomas. These designations underscore the potential of LP-284 to address unmet medical needs in rare and aggressive cancers.
The Notice of Allowance is a critical step in securing intellectual property rights for LP-284. By extending protection into 2042, Lantern Pharma can potentially attract investment and partnerships to further develop and commercialize the therapy. The additional method-of-use claims may also provide a competitive advantage by covering specific applications of LP-284, including its use in combination with other anti-cancer agents. This could broaden the drug's therapeutic potential and enhance its market exclusivity.
For investors, the patent allowance may signal progress in Lantern's pipeline and validate its AI-driven approach to drug development. The company's RADR platform integrates large-scale genomic and biological data with advanced machine learning to identify patients most likely to benefit from its therapies. Lantern's pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN.
The announcement was disseminated through MissionIR, a specialized communications platform that assists IR firms with syndicated content to enhance visibility of private and public companies. MissionIR is part of the Dynamic Brand Portfolio at IBN, which offers access to wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For more information, visit MissionIR.
The global impact of this patent allowance could be far-reaching. Blood cancers such as MCL and DHL are aggressive and often resistant to standard treatments, leaving patients with limited options. LP-284's potential as a novel therapy, especially when combined with other agents, could improve outcomes for these patient populations. Moreover, the use of AI in drug development, as demonstrated by Lantern's RADR platform, may accelerate the identification of effective treatments and reduce the cost and time associated with clinical trials. This aligns with broader industry trends toward precision medicine and data-driven approaches.
However, challenges remain. The patent has not yet been issued, and the clinical trial is in early stages. Success in later-phase trials is not guaranteed, and regulatory approval is required before LP-284 can be commercialized. Investors should consider these risks alongside the potential benefits. Lantern Pharma's ability to execute its clinical strategy and secure additional intellectual property will be key to its long-term success.
